NCT01874353 2025-08-03Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyAstraZenecaPhase 3 Active not recruiting327 enrolled 21 charts 1 FDA